MERIDIAN BIOSCIENCE INC Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2023 As of Dec 31, 2022	Q4 FY2022 As of Sep 30, 2022	Q3 FY2022 As of Jun 30, 2022	Q2 FY2022 As of Mar 31, 2022	Q1 FY2022 As of Dec 31, 2021	Q4 FY2021 As of Sep 30, 2021	Q3 FY2021 As of Jun 30, 2021	Q2 FY2021 As of Mar 31, 2021	Q1 FY2021 As of Dec 31, 2020	Q4 FY2020 As of Sep 30, 2020	Q3 FY2020 As of Jun 30, 2020	Q2 FY2020 As of Mar 31, 2020	Q1 FY2020 As of Dec 31, 2019	Q4 FY2019 As of Sep 30, 2019	Q3 FY2019 As of Jun 30, 2019	Q2 FY2019 As of Mar 31, 2019	Q1 FY2019 As of Dec 31, 2018	Q4 FY2018 As of Sep 30, 2018	Q3 FY2018 As of Jun 30, 2018	Q2 FY2018 As of Mar 31, 2018
CURRENT ASSETS
Cash and cash equivalents
Accounts receivable, less allowances of $1,327 and $1,325, respectively
Inventories, net
Prepaid expenses and other current assets
Total current assets
PROPERTY, PLANT AND EQUIPMENT
Land
Buildings and improvements
Machinery, equipment and furniture
Construction in progress
Subtotal
Less: accumulated depreciation and amortization
Net property, plant and equipment
OTHER ASSETS
Goodwill
Other intangible assets, net
Restricted cash
Deferred instrument costs, net
Fair value of interest rate swap
Right-of-use assets, net
Deferred income taxes
Other assets
Total other assets

TOTAL ASSETS
CURRENT LIABILITIES
Accounts payable
Accrued employee compensation costs
Accrued interest
Accrued estimated litigation costs
Accrued product recall costs
Acquisition consideration
Current operating lease obligations
Current government grant obligations
Other accrued expenses
Current portion of long-term debt
Income taxes payable
Total current liabilities

NON-CURRENT LIABILITIES
Acquisition consideration
Post-employment benefits
Fair value of interest rate swaps
Long-term operating lease obligations
Long-term debt
Government grant obligations
Long-term income taxes payable
Deferred income taxes
Other non-current liabilities
Total non-current liabilities
SHAREHOLDERS' EQUITY
Common shares, no par value; 71,000,000 shares authorized, 43,999,659 and 43,755,188 shares issued and outstanding, respectively
Additional paid-in capital
Treasury stock, at cost; 9,655 shares
Retained earnings
Accumulated other comprehensive loss
Total shareholders' equity

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

Comments